Kaplan-Meier survival curves comparing study cohorts. OS by FLT3 and NPM1 status in (A) all cases and (B) patients treated on intensive cytarabine-based treatment regimens. RFS by FLT3 and NPM1 status in (A) all cases and (B) patients treated on intensive idarubicin and cytarabine–based treatment regimens.